Compression of HMRlignan pharma grade API into direct-compression tablets without prior granulation is used when the API is supplied with a controlled particle-size distribution and when low drug load permits direct mixing. The material is sifted through a 600 µm conical mill screen to break loose aggregates; achieving this delumping without added heat avoids particle-size drift measured by laser diffraction under USP <429> and Ph. Eur. 2.9.31. A direct-compression platform is typically assembled from 20–35% w/w API, 30–45% w/w microcrystalline cellulose PH-102, 20–30% w/w lactose monohydrate 200M, 4% w/w croscarmellose sodium, 0.75% w/w colloidal silicon dioxide, and 0.75% w/w magnesium stearate. The binder-free blend is mixed in a 600 L bin blender at 12 rpm for 600 rotations, with lubricant added as a final stage at 10 rpm for 120 rotations. Compression is performed on a 45–55-station rotary press with precompression force of 2.5–4.0 kN and main compression force of 8–16 kN, using 12 mm standard concave tooling and press speed 35–50 rpm.

Failure modes associated with direct compression of lipophilic plant lignans include ejection-force drift, punch-face filming, and capping if the material bed is not sufficiently ductile. Micronized HMRlignan with high surface area can develop electrostatic charge during low-humidity operations, producing aggregate formation that changes blend uniformity. When relative humidity falls below 30% RH, electrostatic charge can increase; when it exceeds 60% RH, the API may adsorb surface moisture and cause sticking during compression. Pre-drying of the blend at 40 °C for 2 h may be required if loss on drying exceeds 2.0% w/w. At magnesium stearate levels above 1.0% w/w, tablet tensile strength is reduced and dissolution may become delayed because the hydrophobic lubricant layer limits water ingress. At lubricant levels below 0.25% w/w, production-scale presses may show ejection force increase and tablet edge damage. In-process control therefore includes hardness 60–90 N, friability not more than 1.0% per USP <1216>, disintegration not more than 15 min in 900 mL of 0.1 N hydrochloric acid at 37 ± 0.5 °C per USP <701>, and content uniformity according to USP <905>. Blend uniformity samples are taken from the bin blender and the tablet press feed frame under 21 CFR 211.110 to verify that segregation has not occurred.

Does roller compaction shift HMRlignan capsule release from disintegration-control to pore-diffusion control?

Hard gelatin capsule filling frequently requires a granulated intermediate because direct-compression powder may lack sufficient flow for high-speed dosator or tamping-pin filling. Roller compaction converts HMRlignan powder into ribbons and then into granules without exposing the API to water. Ribbon formation is controlled by roll pressure, roll speed, and roll gap. Milling is performed with a 1.0 mm screen and granule collection is restricted to the 250–710 µm sieve fraction; fines below 150 µm are separated because they can generate static charge and non-uniform fill weight on a 60,000-capsule-per-hour line. Granule bulk density, tapped density, and Carr index are measured according to USP <616> and Ph. Eur. 2.9.34. Fill weight for size 1 or 0 hard gelatin capsules is set between 250 mg and 450 mg, depending on granule density and required dose. Additives include 0.5% w/w sodium stearyl fumarate instead of magnesium stearate to avoid a hydrophobic release lag. Dissolution is evaluated by USP <711> apparatus 2 at 50 rpm in 900 mL of media containing 0.1–0.5% w/w sodium lauryl sulfate; media selection is justified under USP <1092> because pH-dependent solubility may require a surfactant to achieve sink conditions. Published data for HMRlignan-specific roller-compacted capsule dissolution is limited. If enteric protection is required, capsule shells or granule coatings based on methacrylic acid copolymers must be evaluated for moisture sensitivity; gelatine cross-linking can occur if impurity aldehyde levels are not controlled.

Representative process windows for roller compaction of a lipophilic lignan granulation are set out below. The values are platform ranges, not verified HMRlignan registration data.

Injectable HMRlignan presentations must address low aqueous solubility before terminal sterilization is considered. Direct aqueous solutions are generally not feasible at the dose levels used for parenteral delivery; therefore lyophilized formulations or soluble carrier systems are evaluated. A lyophilization platform uses a pre-lyophilization solution composed of the API dissolved in a cosolvent system such as 20% w/w tert-butanol in water with 4.5% w/w mannitol as bulking agent, buffered to pH 7.0–7.4. The solution is filtered through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane under an aseptic processing train according to 21 CFR 211.84 and 21 CFR 211.110. Terminal steam sterilization is avoided unless thermal degradation studies demonstrate acceptable assay preservation; published data for HMRlignan terminal sterilization is limited.

Freeze-drying uses a controlled shelf-ramp profile. The filled vials are equilibrated at 5 °C, frozen at shelf temperature -40 °C to -50 °C for 2.0–4.0 h, then primary-dried at -25 °C to -15 °C with chamber pressure 50–100 mTorr (6.7–13.3 Pa). Secondary drying is performed at +20 °C to +30 °C for 8–12 h, with residual moisture determined by Karl Fischer titration under Ph. Eur. 2.5.12 and control set below 1.0% w/w. Cake integrity is inspected for meltback, shrinkage, or collapse; collapse occurs when the product temperature exceeds the collapse temperature of the cosolvent-solute matrix. Container closure integrity is verified by USP <1207>. Subvisible particulate matter is tested under USP <788>; because the presentation is a small-volume parenteral, the relevant acceptance limits are tied to the light obscuration test method.

For injectable development, release and stability tests are anchored to the following methods.

When a sustained-release injectable suspension is selected, particle-size control and zeta potential define injectability

An injectable suspension of HMRlignan is considered when oral bioavailability is not acceptable or when depot presentation is required. The API is wet-milled under high shear to a particle-size target of D50 1–3 µm and D90 <10 µm, measured by laser diffraction according to USP <429>. The suspending vehicle contains 0.5–1.0% w/w poloxamer 188 as wetting agent and 0.3–0.5% w/w sodium carboxymethylcellulose as viscosity modifier; tonicity is adjusted with 0.9% w/w sodium chloride or 4.5% w/w mannitol. The milled suspension is homogenized and then encapsulated under aseptic conditions because terminal sterilization may alter particle-size distribution or crystalline habit. Published data for HMRlignan autoclave stability in suspension is limited.

Syringeability is assessed through a 21G × 1 inch needle using a texture analyzer at 1 mm/s crosshead speed; injection force should be recorded and controlled because excessive force may indicate particle aggregation or viscosity drift. Resuspendability after storage is measured by sedimentation ratio and visual inspection. A zeta potential outside the range of -25 mV to +25 mV can indicate instability, but for sterically stabilized formulations this boundary is not absolute. Particle-size distribution and polymorphic form are rechecked after 30 °C/65% RH storage and after freeze-thaw cycling. Incompatibility with silicone oil from prefilled syringe barrels should be evaluated because hydrophobic API particles can localize at the oil-water interface.

Extrusion-spheronization and high-shear wet granulation convert HMRlignan into free-flowing oral granules for sachets, sprinkle capsules, or compression intermediates. In high-shear wet granulation, the dry blend is prepared from API, lactose monohydrate, and microcrystalline cellulose; a binder solution containing 2–4% w/w hydroxypropyl cellulose in purified water is sprayed at a controlled rate. The impeller is operated at 200–400 rpm and the chopper at 1500–2000 rpm; wet massing continues until target impeller torque is reached. The wet granulate is passed through a 6.35 mm screen, dried in a fluid-bed dryer to loss on drying not more than 2.0% w/w, and dry-milled through a 1.0 mm screen. Alternatively, extrusion-spheronization can yield dense granules with higher sphericity and narrower size distribution. The wet mass is extruded through a 0.8 mm or 1.0 mm screen at a feed rate of 30–50 g/min and spheronized on a cross-hatched plate at 800–1200 rpm for 3–5 min.

For sachet filling, rotational speed and auger size are adjusted to maintain fill weight variation below 5% RSD across a batch. Granule particle-size distribution is checked by analytical sieving under Ph. Eur. 2.9.38 or USP <786>; residual moisture above 2.5% w/w can cause sticking during tableting or caking in sachets, while overdried granules below 1.0% w/w may become brittle and generate fines. Disintegration time of the unpacked granules or final tablets is measured according to USP <701>. If the granules are intended for reconstitution or sprinkle administration, dose uniformity is confirmed under USP <905> and microbial quality is controlled under USP <61> and USP <62> because high moisture during granulation can support bioburden growth if drying cycles are not validated.